CurifyLabs, the Finnish-American startup that builds 3D printers designed to sit behind a pharmacy counter rather than on a maker's desk, has closed a $14 million Series A round to push its dose-printing hardware further into the US healthcare system. The round, announced July 6, 2026, was co-led by Nordic venture firms Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.), Lifeline Ventures, and a group of CurifyLabs' own US customers and employees.
If the name doesn't ring a bell outside pharma-adjacent circles, that's by design. CurifyLabs isn't chasing hobbyists, cosplayers, or even industrial manufacturers — it's building additive manufacturing hardware for compounding pharmacists, the licensed professionals who mix custom-dosed medications for patients who can't be served by a mass-produced pill. The company's flagship machine, the PharmaPrinter Aurum, is part of what CurifyLabs calls its Compounding System Solution, and it extrudes and compounds personalized medication doses on-site. CurifyLabs says pharmacies in 21 US states already run its printers, on top of its existing European footprint, and that its machines collectively compound thousands of doses a day.
From Helsinki Lab to Jacksonville Beachhead
Founded in 2021 and headquartered jointly in Helsinki and Jacksonville, Florida, CurifyLabs has spent the last several years threading a needle that trips up most medical-device startups: building manufacturing hardware that a regulator will actually let you plug in and use on real patients. The PharmaPrinter Aurum is ISO 13485 certified — the quality-management standard for medical device manufacturing — and the company says its compounding process is compliant with FDA 503A and 503B regulations governing non-sterile pharmacy compounding, the two federal frameworks that respectively cover traditional compounding pharmacies and larger outsourcing facilities.
That regulatory footing is arguably the more interesting story than the printer itself. Plenty of companies have demonstrated that a nozzle can deposit a dose-controlled tablet layer by layer; far fewer have gotten a machine cleared to do that inside the legal boundaries pharmacists already operate under. CurifyLabs' pitch is that the Aurum slots into existing 503A/503B non-sterile compounding workflows rather than asking regulators or pharmacies to invent a new category from scratch.
Speed as the Selling Point
According to the company, the PharmaPrinter Aurum compounds medication doses up to nine times faster than manual compounding methods. In an industry where a pharmacist or technician might spend real time weighing, mixing, and hand-forming a single custom dose — particularly for pediatric patients, hospice care, or anyone who needs a strength or combination that doesn't exist as a commercial product — that kind of throughput gain is the difference between compounding being a boutique service and a scalable one.
CEO and founder Charlotta Topelius framed the round in more modest terms than a typical funding-announcement quote might suggest. "This investment reflects the conviction our partners have in what we're building," she said in the announcement, adding that CurifyLabs has "set a high bar for clinical rigor, product quality, and customer support" and that the new capital "gives us the resources to raise that bar further." The new funding is earmarked for expanding US operations, strengthening the company's supply chain, enhancing customer support, and accelerating product development — not a single flashy new factory, but the unglamorous plumbing of a hardware company trying to scale inside a regulated industry.
Sandwater partner Morten E. Iversen, whose firm co-led the round, put the investment thesis in market terms: "Personalized medicine is one of the most important frontiers in healthcare enabling better patient outcomes and is experiencing solid growth," he said, adding that CurifyLabs "has built something rare — technology that combines clinical rigor with the speed and precision that busy pharmacy teams depend on." HealthCap partner Daniel Karsberg, the round's other co-lead, framed the bet around the founding team: HealthCap has backed more than 136 life sciences companies over three decades, he said, and what separates the best founders is combining scientific depth with real-world execution — "the CurifyLabs team has done exactly that." It's a vote of confidence from two investors who specialize in healthcare infrastructure, not desktop hardware.
A Different Kind of AM Investment Story
3DPrint.com's coverage of the raise, written by Matt Kremenetsky, places the deal against a broader 2026 investment backdrop in which defense, space, and AI applications have dominated additive manufacturing's funding headlines and attention. As Kremenetsky put it, with verticals like defense and space and opportunities like the AI boom currently absorbing so much of the AM industry's focus, "it's easy to forget one of the original strategic sectors driving early AM adoption: medical." CurifyLabs' raise is notable partly because it runs counter to that trend: it's a bet on AM as clinical infrastructure rather than aerospace or AI-adjacent hardware, and on pharmacy compounding specifically as the wedge into the US healthcare market.
That framing also helps explain why the round is relatively modest by AM-funding standards. Unlike metal-printing plays serving defense primes, CurifyLabs isn't selling multimillion-dollar production cells to a handful of large customers — it's selling a compounding tool that needs to fit the budget and workflow of individual and regional pharmacies, one state's regulatory environment at a time. Getting to 21 states already suggests the company has been doing that unglamorous, state-by-state pharmacy board and regulatory legwork for a while before this raise ever made headlines.
What It Means for Makers
Most FilamentFeed readers aren't going to be shopping for a PharmaPrinter Aurum — this isn't a desktop FDM machine, and it's not aimed at anyone without a pharmacy license and a controlled-substance-appropriate facility. But the CurifyLabs raise is still worth watching for a few reasons that matter to the broader 3D printing community.
First, it's another data point in additive manufacturing's slow migration from "prototyping curiosity" to "regulated production tool" in yet another vertical. The same arguments that took FDM and resin printers from hobbyist garages into dental labs, orthotics clinics, and now pharmacy compounding rooms are arguments about customization at production speed — exactly the pitch makers have been making for desktop printing for over a decade, just now validated at ISO-certification scale.
Second, it's a reminder that the most defensible 3D printing businesses right now aren't necessarily the ones with the flashiest hardware — they're the ones that did the hard, slow work of regulatory compliance before scaling. CurifyLabs' ISO 13485 certification and FDA 503A/503B compliance took years to secure, and that's precisely what makes a $14 million round meaningful rather than merely another additive manufacturing headline in a year full of them. For anyone eyeing 3D printing as more than a hobby, the lesson is the same one it's always been: the printer is rarely the hard part.
